Hema Now: Episode 21 The Global Perspectives on Myeloma

In this episode, Jonathan Sackier welcomes Claudio Cerchione, haematologist and researcher at the Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. From his early interest in plasma cell disorders, Cerchione shares key insights into the evolution of multiple myeloma (MM) research, the rising role of minimal residual disease (MRD), and promising developments in monoclonal antibodies and CAR-T therapy. He also reflects on standout moments from recent European Hematology Association (EHA) Congress and American Society of Clinical Oncology (ASCO) Annual Meeting, and shares his hopes for the future of haematology. Timestamps: 2:14: Memorable career experiences for Claudio 4:20 Biggest breakthrough in MM 5:10 Interest in plasma cell disorders 6:30 A surprising fact about multiple myeloma 7:40 Claudio’s top choice for a dinner party guest 10:30 The importance of MRD in haematology 13:00 Monoclonal antibodies and CAR-T therapies 19:00 Current challenges 22:22 Claudio’s key EHA and ASCO takeaways 28:30 Claudio’s three magic wishes